These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2104 related articles for article (PubMed ID: 27931088)

  • 1. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
    Fadini GP; Bonora BM; Avogaro A
    Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
    Wang Y; Desai M; Ryan PB; DeFalco FJ; Schuemie MJ; Stang PE; Berlin JA; Yuan Z
    Diabetes Res Clin Pract; 2017 Jun; 128():83-90. PubMed ID: 28448895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
    Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
    Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
    Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
    Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
    Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
    Erondu N; Desai M; Ways K; Meininger G
    Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
    Bamgboye AO; Oni IO; Collier A
    Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
    Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
    Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 106.